At a recent Cardinal Health Specialty Summit, 83 oncology healthcare professionals were surveyed on their perceptions of CAR T-cell therapy and its evolving role in cancer patient management. While providers express optimism regarding the therapy's unprecedented efficacy in certain cancer types, they retain reservations due to substantial financial burdens and its complex administration.
Download the whitepaper to learn the latest provider perceptions on CAR-T as well as key takeaways for biopharma companies.